Multiparticulates Melt-Congeal Core Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional spray-coating methods using sugar cores for pharmaceutical compositions face issues such as friability, non-uniform coating, and rapid drug release due to water absorption, leading to inconsistent dissolution rates and processing challenges for oral dosage forms.
Innovation Solution
A pharmaceutical composition featuring a melt-congeal core with a matrix material, such as waxes or fatty acid esters, surrounded by a solid amorphous dispersion layer of a drug and polymer, which is more stable, easier to coat, and less prone to water absorption, allowing for controlled drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional sugar cores are used for spray-coating, then the core provides a substrate for coating, but the cores are friable and break apart into smaller pieces during the coating process
Solution Approach 1:
The patent changes the physical-chemical parameters of the core material by using melt-congealed cores with controlled melting points and solidification properties. This transforms the core from a friable sugar-based material into a more robust structure that maintains integrity during spray-coating while still allowing controlled drug release.
Solution Approach 2:
The invention uses composite core structures combining melt-congealed materials with specific polymers and matrices that provide both mechanical strength and controlled porosity. This composite approach resolves the contradiction by creating a core that is both structurally sound during processing and permeable for drug release.
2Quantity of substance
If spray-coating is performed for extended periods to build sufficient coating thickness, then the coating provides adequate drug loading, but the average core size decreases due to breakage, resulting in changing size distribution
Solution Approach 1:
The patent applies preliminary action by pre-forming robust melt-congealed cores that are resistant to breakage before the spray-coating process. This preliminary strengthening of the core structure allows extended coating times to achieve sufficient drug loading without the cores breaking apart and changing size distribution.
3Speed
If small cores are used to achieve faster dissolution rates, then the dissolution rate increases, but the cores become difficult to obtain in small sizes and have increased surface irregularities
Solution Approach 1:
The patent changes the formation parameters of small cores by using melt-congealing processes that can produce uniform small-sized cores with smooth surfaces. This parameter change allows achieving fast dissolution rates through small size while maintaining manufacturability and surface uniformity that are difficult to obtain with conventional sugar cores.
4Adaptability or versatility
If sugar cores are used, then the cores are readily available, but the sugar acts as an osmogen and rapidly absorbs water, causing the multiparticulate to rupture and prematurely release the drug
Solution Approach 1:
The patent changes the chemical composition parameters of the core by replacing sugar-based materials with melt-congealed cores having different hygroscopic properties. This parameter change eliminates the osmotic effect that causes rapid water absorption and premature drug release, while maintaining the availability and processability of the cores.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of melt-congeal cores provides uniform multiparticulates with controlled drug release, improved processing stability, and adjustable dissolution rates, enhancing the formulation of oral dosage forms by minimizing batch-to-batch variability and maintaining drug stability.
Implementation Method 1
The melt-congeal core comprises a matrix material present in an amount of at least 30 wt % of the core. The matrix material is solid at 25° C. The matrix material has a melt temperature of less than 200° C.
Implementation Method 2
spray-drying process to form a solid amorphous dispersion of the drug in the polymer to improve the bioavailability of poorly soluble drugs
Implementation Method 3
spray-coat the drug and polymer onto an inert core
Data Source
AI summary
A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.